Non-Hodgkin Lymphoma
Showing NaN - NaN of 15
Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma Trial in United States (NKTR-255 at 1.5 µg/kg, NKTR-255
Recruiting
- Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NKTR-255 at 1.5 µg/kg
- +3 more
-
La Jolla, California
- +26 more
Jan 10, 2023
Non-Hodgkin Lymphoma Trial in Worldwide (Tisagenlecleucel after optional bridging and lymphodepleting chemo, Platinum-based
Active, not recruiting
- Non-Hodgkin Lymphoma
- Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
- Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
-
La Jolla, California
- +66 more
Jan 6, 2023
Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in United States (JCAR017 (lisocabtagene
Active, not recruiting
- Non-Hodgkin Lymphoma
- +4 more
- JCAR017 (lisocabtagene maraleucel) single-dose schedule
- JCAR017 (lisocabtagene maraleucel) 2-dose schedule
-
Birmingham, Alabama
- +24 more
Nov 21, 2022
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma Trial in Chicago, Rochester, Cleveland (Venetoclax, Umbralisib, Ublituximab)
Terminated
- Chronic Lymphocytic Leukemia
- Non-Hodgkin Lymphoma
- Venetoclax
- +3 more
-
Chicago, Illinois
- +2 more
Aug 19, 2022
NSCLC, Renal Cell Cancer, Colorectal Cancer Trial in Australia, United States (CPI-006, CPI-006 + ciforadenant, CPI-006 +
Active, not recruiting
- Non-Small Cell Lung Cancer
- +12 more
- CPI-006
- +2 more
-
Tucson, Arizona
- +26 more
Aug 1, 2022
B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma Trial in Worldwide (CTX110)
Recruiting
- B-cell Malignancy
- +3 more
- CTX110
-
Los Angeles, California
- +27 more
May 6, 2022
Collecting and Storing Tissue Samples From Rare or Cutaneous
Active, not recruiting
- Adult Immunoblastic Lymphoma
- +12 more
- Cytology Specimen Collection Procedure
-
Birmingham, Alabama
- +129 more
Mar 23, 2022
Non-hodgkin Lymphoma, Hodgkin Lymphoma, Lymphoma Trial in Chicago (Radiation - Dose Level 0, Radiation - Dose Level 1, Radiation
Recruiting
- Non-hodgkin Lymphoma
- +2 more
- Radiation - Dose Level 0
- +4 more
-
Chicago, IllinoisUniversity of Chicago
Dec 3, 2021
Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma Trial in Worldwide (brentuximab vedotin, doxorubicin,
Completed
- Anaplastic Large-Cell Lymphoma
- +2 more
- brentuximab vedotin
- +4 more
-
Gilbert, Arizona
- +143 more
Nov 1, 2021
The Second Multicenter Hemophilia Cohort Study
Completed
- Liver Decompensation
- +2 more
-
Tucson, Arizona
- +47 more
Dec 14, 2019
Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in United States (FT-1101, Azacitidine)
Completed
- Acute Myeloid Leukemia
- +3 more
-
Los Angeles, California
- +7 more
Jun 25, 2019
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin Lymphoma Trial in United States (Duvelisib, Venetoclax)
Withdrawn
- Chronic Lymphocytic Leukemia
- +2 more
-
Tucson, Arizona
- +9 more
Jul 22, 2016
Non-Hodgkin Lymphoma, Hodgkin Disease, Thrombocytopenia Trial in Worldwide ((PN-152,243)/ PN-196,444)
Completed
- Non-Hodgkin Lymphoma
- +2 more
- (PN-152,243)/ PN-196,444
-
Phoenix, Arizona
- +37 more
May 3, 2007